comparemela.com

Latest Breaking News On - More such health news - Page 7 : comparemela.com

Roche: FDA Grants Breakthrough Device Designation For Bood Test Measuring Lp(a)

Swiss drug major Roche Holding AG (RHHBY) announced Wedensday that the Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.

Switzerland
Swiss
Jay-bradner
Roche-holding
Drug-administration
More-such-health-news
Amgen
Breakthrough-device-designation

Irvington Seafood Recalls 1 Lb. Packages Of Crabmeat

Irvington, Alabama -based Irvington Seafood is recalling its 1 lb. packages of "Crabmeat: Jumbo, Lump, Finger, and Claw meat" citing the potential to be contaminated with Listeria monocytogenes, according to the U.

Irvington
Alabama
United-states
Mississippi
Kevin-sakprasit
Jen-breakfast-burritos
Analytical-inc
Hormel-foods-sales
Drug-administration
More-such-health-news
Hormel-foods-corp
Planters

Roche, Genentech: Inavolisib Gets FDA Breakthrough Status To Treat Breast Cancer With Mutation

Swiss drug major Roche Holding AG (RHHBY) and its U.S. Unit Genentech announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for inavolisib to treat advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Switzerland
Swiss
Levi-garraway
European-medicines-agency
More-such-health-news
Head-of-global-product-development
Roche-holding
Drug-administration
Breakthrough-therapy-designation
Therapy-designation
Chief-medical-officer
Global-product-development

Lilly Reports Positive Phase 3 Trial Results Of Mirikizumab In Crohn's Disease

Drug major Eli Lilly and Co. (LLY) announced Tuesday that its pivotal Phase 3 VIVID-1 study of mirikizumab in Crohn's disease showed that more than one-half of patients achieved clinical remission at one year, including patients with previous biologic failure.

Washington
United-states
Eli-lilly
Mark-genovese
More-such-health-news
Digestive-disease-week
Lilly-immunology

Biocon Biologics: FDA Approves YESAFILI As First Interchangeable Biological Product To Eylea

(RTTNews) - Biocon Biologics, a subsidiary of Biocon Ltd, announced the FDA has approved the company s first-to-file application for Yesafili, an .

United-states
Biocon-biologics
Shreehas-tambe
Biocon-ltd
More-such-health-news

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.